Breast AI Research Portfolio

Rooted in Research. Optimized for Outcomes.

Redefining what breast cancer detection can be.

  • ScreenPoint Medical Research and Evidence in Breast AI

Not all research is created equal

Born from the collaboration of two leading researchers in image processing, ScreenPoint’s origins in applied academia required us to be relentlessly focused on pushing frontiers in AI in breast imaging. Clinical research collaborations have been integral to our growth and our credibility.

1

Enhanced workflow

Whether you are reading DBT studies in a single reader screening environment like the United States, or identifying lower-risk studies for reducing reading burden in a double reading screening environment, Transpara saves practicing radiologists time – without compromising on clinical quality.

Enhanced workflow
2

Greater confidence

Reading faster has no value without confidence in the results. Transpara’s unmarked studies (70% of a typical screening population) have a 99.97% negative predictive value. These results save ~26% of reading time on DBT studies (Van Winkel, et al, 2021) or up to 44% of workload in a FFDM double-reading environment (Hernström, et al, 2025) while improving the cancer detection rate. Time saved can also save lives.

Greater confidence
3

Consistent results

One of the barriers to confident mammography reading is breast density. Human sensitivity for breast cancer on mammograms can drop from around 80% in the least dense breast tissue to between 50-60% in the densest breasts. Transpara analysis is not affected by the visual characteristics of density in the same way.

Consistent results

Our Breast AI Research Portfolio

The Transpara Breast AI Suite is backed by the largest body of research and the first randomized controlled trial (search "MASAI") in Breast AI.
Click a study to learn more.
 
 

For more information and the latest news, head to our Insights Page →